Cargando…

Anemia as a useful biomarker in patients with diffuse large B-cell lymphoma treated with R-CHOP immunochemotherapy

The aim of the current study is to evaluate the prognostic value of anemia, an easily estimable parameter in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP) immunochemotherapy. A total of 157 patients with...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hong, Junshik, Woo, Hyun Seon, Kim, Hyunchul, Ahn, Hee Kyung, Sym, Sun Jin, Park, Jinny, Ahn, Jeong Yeal, Cho, Eun Kyung, Shin, Dong Bok, Lee, Jae Hoon
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Blackwell Publishing Ltd 2014
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4317957/ https://www.ncbi.nlm.nih.gov/pubmed/25263825 http://dx.doi.org/10.1111/cas.12544

Ejemplares similares

Additional rituximab-CHOP (R-CHOP) versus involved-field radiotherapy after a brief course of R-CHOP in limited, non-bulky diffuse large B-cell lymphoma: a retrospective analysis
por: Hong, Junshik, et al.
Publicado: (2010)

Baseline renal function as a prognostic indicator in patients with newly diagnosed diffuse large B-cell lymphoma
por: Hong, Junshik, et al.
Publicado: (2016)

Prognostic Factors for Risk Stratification of Patients with Recurrent or Metastatic Pancreatic Adenocarcinoma Who Were Treated with Gemcitabine-Based Chemotherapy
por: Park, Inkeun, et al.
Publicado: (2016)

Randomized Phase II Study of Pemetrexed Versus Gefitinib in Previously Treated Patients with Advanced Non-small Cell Lung Cancer
por: Kim, Young Saing, et al.
Publicado: (2016)

Body Composition as a Predictor of Toxicity and Prognosis in Patients with Diffuse Large B-Cell Lymphoma Receiving R-CHOP Immunochemotherapy
por: Guo, Jiaxun, et al.
Publicado: (2021)

Epidermal growth factor receptor mutation and pattern of brain metastasis in patients with non-small cell lung cancer
por: Baek, Min Young, et al.
Publicado: (2018)

Screening of key genes associated with R-CHOP immunochemotherapy and construction of a prognostic risk model in diffuse large B-cell lymphoma
por: Liu, Ran, et al.
Publicado: (2019)

The Prognostic Impact of Comorbidities in Patients with De-Novo Diffuse Large B-Cell Lymphoma Treated with R-CHOP Immunochemotherapy in Curative Intent
por: Kocher, Florian, et al.
Publicado: (2020)

Emerging Role of Consolidative Radiotherapy After Complete Remission Following R-CHOP Immunochemotherapy in Stage III–IV Diffuse Large B-Cell Lymphoma: A Single Institutional and Case-Matched Control Study
por: Hong, Ji Hyun, et al.
Publicado: (2021)

Cervical Lymphadenopathy Mimicking Angioimmunoblastic T-Cell Lymphoma after Dapsone-Induced Hypersensitivity Syndrome
por: Rim, Min Young, et al.
Publicado: (2012)

The impact of sMICA/sMICB on immunochemotherapy outcomes in newly diagnosed diffuse large B-cell lymphoma
por: Yoon, Sang Eun, et al.
Publicado: (2023)

A phase I/II study of bortezomib plus CHOP every 2 weeks (CHOP-14) in patients with advanced-stage diffuse large B-cell lymphomas
por: Kim, Jeong Eun, et al.
Publicado: (2012)

Pemetrexed versus Gefitinib versus Erlotinib in Previously Treated Patients with Non-Small Cell Lung Cancer
por: Hong, Junshik, et al.
Publicado: (2010)

Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) chemotherapy for diffuse large B-cell lymphoma in pregnancy may be associated with preterm birth
por: Lee, Eun Ju, et al.
Publicado: (2014)

A Case of B-cell Lymphoma, Unclassifiable, with Features Intermediate between Diffuse Large B-cell Lymphoma and Burkitt Lymphoma in a Korean Child
por: Ahn, Jeong Yeal, et al.
Publicado: (2012)

Pattern of failure and optimal treatment strategy for primary gastric diffuse large B-cell lymphoma treated with R-CHOP chemotherapy
por: Kang, Hye Jin, et al.
Publicado: (2020)

Consolidative Radiotherapy after Complete Remission following R-CHOP Immunochemotherapy in Stage III–IV Diffuse Large B-Cell Lymphoma Patients: A Systematic Review and Meta-Analysis
por: Choi, Kyu-Hye, et al.
Publicado: (2023)

Clinical significance of rituximab infusion-related reaction in diffuse large B-cell lymphoma patients receiving R-CHOP
por: Cho, Kyoung Min, et al.
Publicado: (2019)

An integrated prognostic model for diffuse large B‐cell lymphoma treated with immunochemotherapy
por: Rodríguez, Marta, et al.
Publicado: (2022)

A multi-institutional and case-matched control study on treatment outcomes of consolidative radiotherapy after a full course of R-CHOP compared with R-CHOP alone in Stage I–II diffuse large B-cell lymphoma (KROG 17-02)
por: Chung, Mi Joo, et al.
Publicado: (2019)

N-ras Mutation Detection by Pyrosequencing in Adult Patients with Acute Myeloid Leukemia at a Single Institution
por: Jeong, Ji Hun, et al.
Publicado: (2013)

Treatment results of radiotherapy following CHOP or R-CHOP in limited-stage head-and-neck diffuse large B-cell lymphoma: a single institutional experience
por: Jeong, Jae-Uk, et al.
Publicado: (2017)

R-CHOP chemoimmunotherapy followed by autologous transplantation for the treatment of diffuse large B-cell lymphoma
por: Lee, Hong Ghi, et al.
Publicado: (2014)

Oxaliplatin-Induced Immune-Mediated Thrombocytopenia: A Case Report
por: Woo, Hyun Sun, et al.
Publicado: (2015)

Prognostic factors in primary diffuse large B-cell lymphoma of adrenal gland treated with rituximab-CHOP chemotherapy from the Consortium for Improving Survival of Lymphoma (CISL)
por: Kim, Yu Ri, et al.
Publicado: (2012)

Prognostic significance of BLK expression in R-CHOP treated diffuse large B-cell lymphoma
por: Choi, Soyeon, et al.
Publicado: (2022)

Real world data on follicular lymphoma patients treated by rituximab-containing immunochemotherapy and rituximab maintenance
por: Kim, Hee Kyung, et al.
Publicado: (2020)

Acute Exacerbation of Chronic Hepatitis B During Thalidomide Therapy for Multiple Myeloma: A Case Report
por: Bang, Soo-Mee, et al.
Publicado: (2004)

A modified prognostic model in patients with diffuse large B-cell lymphoma treated with immunochemotherapy
por: Zhao, Peiqi, et al.
Publicado: (2021)

Clinical Response to CHOP vs. R-CHOP in Adult Patients with Diffuse Large B-Cell Lymphomas
por: Tariq, Ayesha, et al.
Publicado: (2018)

Patterns of Neutropenia and Risk Factors for Febrile Neutropenia of Diffuse Large B-Cell Lymphoma Patients Treated with Rituximab-CHOP
por: Choi, Yong Won, et al.
Publicado: (2014)

Epidermal Growth Factor Receptor Mutations and the Clinical Outcome in Male Smokers with Squamous Cell Carcinoma of Lung
por: Park, Se Hoon, et al.
Publicado: (2009)

Clinical Analysis of the HBV Infection Status of 135 Patients with Diffuse Large B Cell Lymphoma Treated with R-CHOP or CHOP/CHOP-Like Chemotherapy
por: Guo, Wei, et al.
Publicado: (2015)

Association of Occupational Pesticide Exposure With Immunochemotherapy Response and Survival Among Patients With Diffuse Large B-Cell Lymphoma
por: Lamure, Sylvain, et al.
Publicado: (2019)

Prediction of survival by applying current prognostic models in diffuse large B-cell lymphoma treated with R-CHOP followed by autologous transplantation
por: Lee, Hong Ghi, et al.
Publicado: (2015)

Campylobacter fetus spondylodiscitis during immunochemotherapy for non-Hodgkin's lymphoma
por: Cunha, Jéssica Santos, et al.
Publicado: (2021)

The Feasibility of Virtual Toxicity Assessments in Lymphoma Patients Receiving Immunochemotherapy
por: Runge, John S., et al.
Publicado: (2020)

Low Frequency and Variability of FLT3 Mutations in Korean Patients with Acute Myeloid Leukemia
por: Bang, Soo-Mee, et al.
Publicado: (2008)

First‐line R‐CVP versus R‐CHOP induction immunochemotherapy for indolent lymphoma with rituximab maintenance. A multicentre, phase III randomized study by the Polish Lymphoma Research Group PLRG4
por: Walewski, Jan, et al.
Publicado: (2019)

Prognostic Value of AML1/ETO Fusion Transcripts in Patients with Acute Myelogenous Leukemia
por: Cho, Eun Kyung, et al.
Publicado: (2003)

Cannot write session to /tmp/vufind_sessions/sess_od025s0blitlrh98aoskp63042